Ann Dermatol.  2016 Feb;28(1):94-97. 10.5021/ad.2016.28.1.94.

Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit

• Byun SY
• Kim BR
• Choi JW
• Youn SW

• KMID: 2429488
• DOI: http://doi.org/10.5021/ad.2016.28.1.94

Abstract

Because nail psoriasis is difficult to treat, therapy with many biological drugs has been attempted. Ustekinumab is approved for chronic plaque psoriasis and psoriatic arthritis (PsA), with some trials reporting nail improvement using this agent. A 51-year-old man with severe chronic plaque psoriasis had severe involvement of all fingernails and toenails, with accompanying nail fold psoriasis. He also had PsA of the small joints of the fingers. Despite multiple conventional therapies, the nail lesions did not improve, and his nail psoriasis severity index score was 97. After a fourth ustekinumab injection, most of the fingernail psoriasis was resolved, and only hyperkeratosis remained on both large toenails. Because the nail plate, nail fold, and small joints of the fingers are closely apposed structures within a small area, cytokines produced from the nail units overflow to the nail fold and small joints and can induce nail fold psoriasis and PsA.

Keyword

Arthritis; Nail diseases; Psoriasis; Psoriatic; Severity of illness index; Ustekinumab

MeSH Terms

Arthritis
Arthritis, Psoriatic
Cytokines
Fingers
Humans
Joints
Middle Aged
Nail Diseases
Nails
Psoriasis*
Severity of Illness Index
Ustekinumab
Cytokines

Figure

• 

  Fig. 1 Severe 20-nail and nail fold psoriasis before ustekinumab treatment. Fingernails showing relatively less change than the toenails because of the effect of repetitive triamcinolone intralesional injections. Proximal nail fold atrophy caused by steroid injection can be seen.

• 

  Fig. 2 Improvement in nail psoriasis after the fourth injection of ustekinumab. There is complete remission of fingernail psoriasis. Both large toenails show subungual hyperkeratosis, which was completely resolved after treatment.

Reference

1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007; 57:1–27.

2. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009; 13:Suppl 2. S102–S106.

3. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366:1367–1374.

4. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014; 170:398–407.

5. Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015; 29:353–360.

6. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003; 49:206–212.

7. Neerja Puri BBM. Nail changes in psoriasis - A profile. J Pakistan Assoc Dermatol. 2011; 21:165–169.

8. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137:280–284.

9. Youn SW, Kim BR, Lee JH, Song HJ, Choe YB, Choi JH, et al. Comparison of treatment goals for moderate-to-severe psoriasis between korean dermatologists and the European consensus report. Ann Dermatol. 2015; 27:184–189.

10. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009; 23:Suppl 1. 15–21.

11. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010; 69:394–399.

12. Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008; 18:683–687.

13. Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010; 146:1315–1316.

14. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. 2013; 24:96–100.

15. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford). 2007; 46:253–256.